BIT Capital’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-21,011
Closed -$428K 124
2024
Q4
$428K Sell
21,011
-8,751
-29% -$224K 0.03% 87
2024
Q3
$867K Sell
29,762
-56,415
-65% -$1.4M 0.08% 77
2024
Q2
$2M Buy
86,177
+4,177
+5% +$80.2K 0.16% 55
2024
Q1
$1.68M Buy
+82,000
New +$1.54M 0.12% 72

Other funds holding DNLI

BIT Capital's DNLI Position: Q1 2025 in Review

BIT Capital sold out of Denali Therapeutics (DNLI) in Q1 2025, closing a stake of 21,011 shares — an estimated $428K sold.

BIT Capital first reported a position in DNLI in Q1 2024 and held it in 4 quarters. The position peaked at $2M in Q2 2024. 222 funds tracked by Wall St. Rank hold DNLI as of Q1 2025.

  • BIT Capital reported no remaining Denali Therapeutics position as of Q1 2025 after selling out during the quarter.
  • BIT Capital sold 21,011 Denali Therapeutics shares in Q1 2025, an estimated $428K.
  • BIT Capital first reported a position in Denali Therapeutics in Q1 2024 and held it in 4 quarters.
  • BIT Capital's Denali Therapeutics position peaked at $2M in Q2 2024.
  • 222 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2025.

Based on BIT Capital's 13F filing for Q1 2025, filed 9 May 2025.